Overview
SGHT market data
Price History
SGHT price chart · 1M
- O
- 8.31
- H
- 8.53
- L
- 8.28
- C
- 8.43
- Vol
- 9,009.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $8.31
- Previous Close
- $8.37
- Day High
- $8.53
- Day Low
- $8.28
- 52 Week High
- $8.84
- 52 Week Low
- $3.87
- 7 Day Return
- +3.44%
- 30 Day Return
- +58.76%
- 90 Day Return
- +72.92%
- 1 Year Return
- +112.61%
- Daily Notional Volume
- $75.9K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.74 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -35.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.19 – $9.24 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $458.3M · P/B 6.56 · P/S 5.50.
Company News
Sight Sciences Announces Updated FDA Indications For TearCare, Effective August 18Benzinga · Aug 19, 2026, 11:10 AM
8-K filing — Sight Sciences, Inc. (SGHT)SEC EDGAR · Aug 10, 2026, 12:21 PM
UBS Maintains Buy on Sight Sciences, Raises Price Target to $8Benzinga · Aug 6, 2026, 7:40 PM
Sight Sciences Raises FY2026 Sales Guidance from $83.000M-$89.000M to $88.000M-$92.000M vs $86.083M EstBenzinga · Aug 5, 2026, 8:35 PM
Sight Sciences Q2 EPS $(0.08) Beats $(0.15) Estimate, Sales $23.388M Beat $21.682M EstimateBenzinga · Aug 5, 2026, 8:12 PM
Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving PremarketBenzinga · Aug 5, 2026, 8:57 AM
Sight Sciences Receives FDA 510(k) Clearance For OMNI Ultra Surgical System; Next-Generation Implant-Free MIGS Device For Primary Open-Angle GlaucomaBenzinga · Aug 4, 2026, 9:39 PM
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $6Benzinga · Jul 8, 2026, 3:50 PM
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $5.15Benzinga · May 28, 2026, 8:07 PM